As evidence of the concept for an immunotherapy consisting of inducing the transient expression of mycobacterial HSP65 or the antigen 85 complex (Ag85) (fibronectin-binding protein) to make melanoma tumors more immunogenic, Tarrant et al., induced subcutaneous tumors using B16-F10 cells transfected with either HSP65 or Ag85 and observed a significant tumor burden reduction in the case of Ag85-B16-F10 tumors but not in the tumors that expressed HSP65, indicating that Ag85 protein is more immunogenic [60]. Here, HSPD1 is linked to neoplasm.